title: [Thalidomide: mechanisms of action and new insights in hematology].
abstract: Purpose. - Thalidomide, a major teratogen drug, was rehabilitated mainly in malignant hemopathy. Current knowledge and key points. - Thalidomide-mechanisms of action are well known, multiple, they combine immunomodulatory, antiangiogenic properties, and the modulation of cytokines, particularly tumour necrosis factor-alpha. Multiple trials are ongoing, however, the main indication remain multiple myeloma with a response rate of 30% in relapsed patients. Future prospects and projects. - New structural analogues of the thalidomide which priviligiate some of the thalidomide-specific mechanisms of action, the selected cytokine inhibitory drugs (SelCIDS) and the immunomodulatory drugs (IMiDs) family are under evaluation. The IMiDs, which mechanism is based on stimulation of T lymphopoiesis rather than inhibition of tumour necrosis factor-alpha, are under clinical trials in multiple myeloma with interesting results.
authors.affiliation: Service des maladies du sang, hôpital Claude-Huriez, CHRU, Lille, France.
authors.forename: X
authors.initials: X
authors.lastname: Leleu
authors.forename: J B
authors.initials: JB
authors.lastname: Micol
authors.forename: R
authors.initials: R
authors.lastname: Guieze
authors.forename: C
authors.initials: C
authors.lastname: Berthon
authors.forename: F
authors.initials: F
authors.lastname: Kuhnovsky
authors.forename: L
authors.initials: L
authors.lastname: Terriou
authors.forename: A S
authors.initials: AS
authors.lastname: Moreau
authors.forename: I
authors.initials: I
authors.lastname: Yakoub-Agha
authors.forename: F
authors.initials: F
authors.lastname: Bauters
authors.forename: T
authors.initials: T
authors.lastname: Facon
mesh_terms: D000686:Amyloidosis / Q000188:drug therapy; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000037:antagonists & inhibitors; D005500:Follow-Up Studies; D005544:Forecasting; D006402:Hematologic Diseases / Q000188:drug therapy*; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use; D000077269:Lenalidomide; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D009101:Multiple Myeloma / Q000188:drug therapy*; D009190:Myelodysplastic Syndromes / Q000188:drug therapy; D055728:Primary Myelofibrosis / Q000188:drug therapy; D012008:Recurrence; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use*; D013997:Time Factors; D008258:Waldenstrom Macroglobulinemia / Q000188:drug therapy
chemical_list: D020533:Angiogenesis Inhibitors; D016207:Cytokines; D007155:Immunologic Factors; D013792:Thalidomide; D000077269:Lenalidomide